Klotho gene therapy - Kogenix Therapeutics

Drug Profile

Klotho gene therapy - Kogenix Therapeutics

Alternative Names: alpha Klotho gene therapy; s-KL gene therapy

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Universitat Autonoma de Barcelona; Vall d-Hebron Research Institute
  • Developer Kogenix Therapeutics; Universitat Autonoma de Barcelona; Vall d-Hebron Research Institute
  • Class Antidementias; Gene therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease; Dementia; Multiple sclerosis

Most Recent Events

  • 07 Nov 2017 Universitat Autònoma de Barcelona and Vall d"Hebron Research Institute have patent protection for Klotho gene therapy (UAB website, November 2017)
  • 31 Oct 2017 Pharmacodynamics data in Alzheimer's disease and Multiple sclerosis released by Kogenix Therapeutics
  • 31 Oct 2017 Klotho gene therapy is licensed to Kogenix Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top